Lung Cancer Clinical Trials in Detroit

Showing 401-420 of 753 trials

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

NCT02482311

This is an open-label, multi-centre, Phase Ib study of AZD1775 designed to assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of AZD1775 monotherapy in patients with advanced solid tumours.

Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

AstraZeneca92 participantsStarted Jul 2015

Fayetteville, Arkansas, United States • San Francisco, California, United States • West Hollywood, California, United States +13 more locations

COMPLETEDPhase 2< 1 mile

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

NCT01104155

This is a Phase 2, multicenter, randomized study of two different dose regimens of eribulin mesylate in combination with intermittent erlotinib in patients with previously treated, advanced non-small cell lung cancer.

Non-small Cell Lung Cancer

Eisai Inc.123 participantsStarted Feb 2010

Bessemer, Alabama, United States • Birmingham, Alabama, United States • Beverly Hills, California, United States +61 more locations

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Lung Cancer Trials in Other Cities

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

Safety Study of SEA-CD40 in Cancer Patients

Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer

RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Other Conditions in Detroit